Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Vaccinations01:51

Vaccinations

44.4K
Overview
44.4K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Meningococcal B Vaccine to Prevent <i>Neisseria gonorrhoeae</i> Infection.

The New England journal of medicine·2026
Same author

Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection.

Nature medicine·2026
Same author

HIV cascade, key indicators, and other epidemiological metrics in Australia (2004-2023): a retrospective analysis.

The Lancet regional health. Western Pacific·2026
Same author

Barriers and Facilitators to Oral HIV Pre-exposure Prophylaxis Use in Australia: A Scoping Review Comparing Findings to Canada, New Zealand, and the United Kingdom.

AIDS and behavior·2026
Same author

A temporal map of B cell diversification mechanisms in mice.

Nature immunology·2026
Same author

The pyrrolidinamide antimalarial drug MMV367 rapidly clears blood-stage <i>Plasmodium falciparum</i> in healthy adults with experimental malaria.

Science translational medicine·2026

相关实验视频

Updated: Jun 26, 2025

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.7K

预测mopox疫苗的疫苗有效性

Matthew T Berry1, Shanchita R Khan1, Timothy E Schlub1,2

  • 1Kirby Institute, University of New South Wales, Sydney, NSW, Australia.

Nature communications
|May 8, 2024
PubMed
概括

修改疫苗安卡拉 (MVA-BN) 接种后的抗体水平与mopox疫苗的有效性相关. 推迟第二剂MVA-BN可能会提供更持久的保护,特别是在疫苗短缺期间.

更多相关视频

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

11.2K
Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells
12:54

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Published on: May 19, 2023

1.9K

相关实验视频

Last Updated: Jun 26, 2025

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice
08:52

Evaluation of Host-Pathogen Responses and Vaccine Efficacy in Mice

Published on: February 22, 2019

10.7K
A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors
09:16

A Simple and Efficient Approach to Construct Mutant Vaccinia Virus Vectors

Published on: October 30, 2016

11.2K
Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells
12:54

Determination of Vaccine Immunogenicity Using Bovine Monocyte-Derived Dendritic Cells

Published on: May 19, 2023

1.9K

科学领域:

  • 免疫学 免疫学 免疫学
  • 疫苗学 疫苗学 疫苗学
  • 流行病学 流行病学

背景情况:

  • 修改的疫苗安卡拉疫苗 (MVA-BN) 对于2022年爆发期间的mopox预防至关重要.
  • MVA-BN的批准依赖于免疫性和动物模型,缺乏临床疗效数据和验证的相关保护.
  • 没有确定的抗体值预测MVA-BN对mpox的有效性.

研究的目的:

  • 为了确定疫苗结合性ELISA终点标位是否预测MVA-BN疫苗对mpox的有效性.
  • 分析疫苗接种后的抗体动力学,以预测保护的耐用性和最佳的剂量间隔.
  • 提供一种基于证据的定量方法,使用抗体测量来评估mopox疫苗的有效性.

主要方法:

  • 系统的文献搜索和对可用的mopox疫苗接种数据的元分析.
  • 疫苗结合抗体标位和报告的疫苗有效性之间的相关性分析.
  • 模拟抗体动力学以预测保护持续时间和剂量间隔的影响.

主要成果:

  • 在疫苗结合抗体标位和疫苗有效性之间观察到显著的相关性,支持抗体作为潜在的保护相关物.
  • 对抗体动力学的分析表明,延迟第二剂MVA-BN剂量可以提高保护的耐用性.
  • 这些发现表明,在资源有限的爆发场景中,延长剂量间隔可能是有利的.

结论:

  • 疫苗结合抗体标位表现有希望,作为mopox疫苗有效性的预测相关值.
  • 优化MVA-BN剂量计划,特别是通过延迟第二剂量,可以改善长期保护.
  • 这项研究提供了一个定量框架,用于利用抗体数据为公众健康策略提供mopox疫苗接种信息.